Autolus is a biopharmaceutical company founded in 2014 that specialises in developing next-generation, programmed T cell therapies for cancer and autoimmune diseases. Its core work centres on T cell programming and the engineering of Chimeric Antigen Receptors (CARs) to create autologous T cell therapies - a field where computational design, data-driven optimisation, and biological engineering converge. The company operates as a fully integrated CAR T organisation across the United Kingdom, Germany, and the United States, with its headquarters in London.
The company's lead product, AUCATZYL (obecabtagene autoleucel, obe-cel), received FDA approval in November 2024 for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Autolus's research has been published in the New England Journal of Medicine and Nature Medicine. Its pipeline spans hematological malignancies, solid tumors, and autoimmune diseases.
Technical roles at Autolus involve work at the intersection of biology and engineering: designing programmed T cells with specific therapeutic behaviours, developing chimeric antigen receptors, and advancing the science of cellular therapy. The company's integrated model - from research through manufacturing and clinical development - offers exposure to the full lifecycle of engineered cell therapies.
